Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1996
Protection against lethal viral infection by vaccination with nonimmunodominant peptidesM Oukka, J C Manuguerra, N Livaditis, et al.International Journal of Peptide and Protein Research|March 1, 1991
Synthesis and biological activity of substance P C-terminal hexapeptide and heptapeptide analoguesG Stavropoulos, K Karagiannis, P Cordopatis, et al.Arzneimittel-Forschung|August 5, 2000
Angiotensin II analogues with sulphur-containing side-chains in position 5. A structure-activity relationship studyJ Pérodin, R Bouley, E Escher, et al.Journal of Peptide Science : an Official Publication of the European Peptide Society|June 9, 2005
Synthesis, liposomal formulation and thermal effects on phospholipid bilayers of leuprolideV Saroglou, S Hatziantoniou, M Smyrniotakis, et al.European Journal of Immunology|November 28, 2000
A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopesS Tourdot, A Scardino, E Saloustrou, et al.Journal of Medicinal Chemistry|July 1, 1988
Importance of the N-terminal domain of the type II angiotensin antagonist sarmesin for receptor blockadeJ Matsoukas, P Cordopatis, U Belte, et al.Medicinal Chemistry (Shariqah (United Arab Emirates))|June 22, 2006
3D solution structure of [Tyr3]octreotate derivatives in DMSO: structure differentiation of peptide core due to chelate group attachment and biologically active conformationG A Spyroulias, A S Galanis, Ch Petrou, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 1, 1997
Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccinationS Tourdot, M Oukka, J C Manuguerra, et al.Journal of Medicinal Chemistry|October 1, 1985
Conformationally restricted C-terminal peptides of substance P. Synthesis, mass spectral analysis and pharmacological propertiesD Theodoropoulos, C Poulos, D Gatos, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2011
Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II studyA Kotsakis, E-K Vetsika, S Christou, et al.Pageof 4